GeneDx Holdings Corp. (Nasdaq: WGS), a leader in genomic insights for rare disease diagnosis, has reported its third quarter 2025 financial results, highlighting strong growth, expanding market leadership, and key strategic advancements. The company’s President and CEO, Katherine Stueland, emphasized that the results reflect not only business momentum but also the real-world impact of GeneDx’s work in transforming healthcare for families affected by rare diseases. In the third quarter of 2025, GeneDx reported total revenue of $116.7 million, up from $76.9 million in the same period of 2024. The company saw significant growth in exome and genome testing volumes, which reached 25,702 tests—up from 19,262 in the third quarter of 2024. This growth, combined with a gross margin expansion to 73.6% (up from 64.3% in 2024), underscores the company’s improving scale and operational efficiency. Kevin Feeley, GeneDx’s CFO, noted that the company is now positioned for sustainable, high-growth, and profitable expansion, supported by a rapidly growing market and strong demand for precision medicine solutions. GeneDx has updated its full year 2025 guidance, raising expectations across key metrics. The company now expects revenue of $425 to $428 million, up from the previous range of $400 to $415 million. Exome and genome revenue growth is now projected at 53% to 55%, up from 48% to 52%. Adjusted gross margin is expected to be between 70% and 71%, and the company anticipates positive adjusted net income in each quarter and for the full year. Key business highlights in the third quarter include the launch of GeneDx Infinity™, the largest rare disease dataset, which powers the company’s ExomeDx™ and GenomeDx™ tests. The platform is central to GeneDx’s mission of enabling earlier, more accurate diagnoses through data and AI. The company also received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, recognizing their potential to provide critical diagnostic insights for life-threatening genetic conditions. This designation supports faster development and review, reinforcing GeneDx’s leadership in genomic medicine. GeneDx expanded access to whole genome sequencing by securing coverage from California Medicaid (Medi-Cal), bringing the total number of states with outpatient coverage for exome or genome testing to 36. The company also launched the Autism Partnership Program with Jaguar Gene Therapy, increasing access to testing for patients with SHANK3-related autism and Phelan-McDermid syndrome. In leadership, GeneDx appointed Lisa Gurry as Chief Business Officer and Dr. Mimi Lee as Chief Precision Medicine Officer to strengthen its engagement with health systems, payers, biopharmaceutical companies, and advocacy groups. Dr. Thomas Fuchs, MD, PhD, was also added to the board, bringing expertise in AI and human health. On the research front, GeneDx presented groundbreaking findings at the American Society of Human Genetics (ASHG) Annual Meeting, including a machine learning study of over 250,000 exome and genome trios that improved the detection of de novo variants. The company also published new data on the genetic basis of autism, identifying over 250 key genes and revealing genetic links to schizophrenia, epilepsy, and bipolar disorder. Additionally, results from the GUARDIAN study on genomic newborn screening (gNBS) showed high enrollment, strong parental satisfaction, and meaningful clinical outcomes, further validating the value of early genetic testing. GeneDx will host a conference call on October 28, 2025, at 8:30 a.m. Eastern Time to discuss the results. Investors can access the live and archived webcast on the company’s investor relations website. The company remains focused on advancing precision medicine, moving from reactive care to proactive, personalized health solutions powered by genomics, data, and innovation.